Petkar Imran, McQuaid Dualta, Dunlop Alex, Tyler Justine, Hall Emma, Nutting Chris
Head and Neck Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Division of Radiotherapy and Imaging, Institute of Cancer Research, London, United Kingdom.
Front Oncol. 2021 Mar 9;11:644767. doi: 10.3389/fonc.2021.644767. eCollection 2021.
To evaluate the inter-observer variation (IOV) in pharyngeal constrictor muscle (PCM) contouring, and resultant impact on dosimetry and estimated toxicity, as part of the pre-trial radiotherapy trial quality assurance (RTQA) within DARS, a multicenter phase III randomized controlled trial investigating the functional benefits of dysphagia-optimized intensity-modulated radiotherapy (Do-IMRT) in pharyngeal cancers.
Outlining accuracy of 15 clinicians' superior and middle PCM (SMPCM) and inferior PCM (IPCM) were retrospectively assessed against gold standards (GS) using volume, location, and conformity indices (CIs) on a pre-trial benchmark case of oropharyngeal cancer. The influence of delineation variability on dose delivered to the constrictor muscles with Do-IMRT and resultant normal tissue complication probability (NTCP) for physician-scored radiation-associated dysphagia at 6 months was evaluated.
For GS, SMPCM, and IPCM volumes were 13.51 and 1.67 cm; corresponding clinician mean volumes were 12.18 cm (SD 3.0) and 2.40 cm (SD 0.9) respectively. High IOV in SMPCM and IPCM delineation was observed by the low DICE similarity coefficient value, along with high geographical miss index and discordance index values. Delineation variability did not significantly affect the mean dose delivered to the constrictors, relative to the GS plan. Mean clinician NTCP was 24.6% (SD 0.6), compared to the GS-NTCP of 24.7%.
Results from this benchmark case demonstrate that inaccurate PCM delineation existed, even with protocol guidelines. This did not impact on delivered dose to this structure with Do-IMRT, or on estimated swallowing toxicity, in this single benchmark case.
作为DARS(一项多中心III期随机对照试验,研究吞咽困难优化调强放疗(Do-IMRT)在咽喉癌中的功能益处)试验前放射治疗试验质量保证(RTQA)的一部分,评估咽缩肌(PCM)轮廓勾画中观察者间差异(IOV)及其对剂量测定和估计毒性的影响。
在一例口咽癌试验前基准病例中,使用体积、位置和适形指数(CIs),针对金标准(GS)回顾性评估15名临床医生对咽缩肌上部和中部(SMPCM)及下部(IPCM)的勾画准确性。评估勾画变异性对Do-IMRT时输送至咽缩肌的剂量以及6个月时医生评分的放射性吞咽困难所致正常组织并发症概率(NTCP)的影响。
对于GS,SMPCM和IPCM的体积分别为13.51和1.67 cm³;相应临床医生的平均体积分别为12.18 cm³(标准差3.0)和2.40 cm³(标准差0.9)。低DICE相似系数值表明SMPCM和IPCM勾画中存在较高的IOV,同时地理遗漏指数和不一致指数值也较高。相对于GS计划,勾画变异性并未显著影响输送至咽缩肌的平均剂量。临床医生的平均NTCP为24.6%(标准差0.6),而GS-NTCP为24.7%。
该基准病例的结果表明,即使有方案指南,PCM的勾画仍存在不准确情况。在这一单基准病例中,这并未影响Do-IMRT时该结构的输送剂量或估计的吞咽毒性。